title: Medical abortion with oral methotrexate and vaginal misoprostol.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of oral methotrexate and vaginal misoprostol for medical abortion.
  
  
  METHODS
  A prospective multicenter trial involved 300 women up to 49 days' gestation seeking elective abortion. Subjects received methotrexate 50 mg orally followed 5-6 days later by misoprostol 800 micrograms vaginally. The misoprostol dose was repeated if abortion did not occur.
  
  
  RESULTS
  Complete abortion occurred in 273 of 299 women (91.3%; 95% confidence interval [CI] 87.5, 94.2%); one woman was lost to follow-up. Abortion occurred within 8 days of the methotrexate in 233 women (77.9%; 95% CI 72.8, 82.5%); the remaining 13.4% of women who aborted did so after a delay of 23.5 +/- 9.8 days (median 23 days, range 10-45). Vaginal bleeding lasted an average of 15 and 11 days in immediate and delayed-success abortions, respectively. Complete abortion rates decreased linearly with increasing body surface area. After methotrexate and misoprostol administration, nausea was reported in 37% and 33%, vomiting in 11% and 18%, diarrhea in 12% and 18%, and subjective fever or chills in 15% and 31% of subjects, respectively.
  
  
  CONCLUSIONS
  Oral methotrexate followed by vaginal misoprostol is effective for abortion and represents an acceptable alternative to intramuscular methotrexate in regimens for medical abortion.
authors.affiliation: Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Magee-Womens Hospital, Pittsburgh, Pennsylvania, USA.
authors.forename: M D
authors.initials: MD
authors.lastname: Creinin
authors.forename: E
authors.initials: E
authors.lastname: Vittinghoff
authors.forename: E
authors.initials: E
authors.lastname: Schaff
authors.forename: C
authors.initials: C
authors.lastname: Klaisle
authors.forename: P D
authors.initials: PD
authors.lastname: Darney
authors.forename: C
authors.initials: C
authors.lastname: Dean
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage* / Q000009:adverse effects; D000028:Abortion, Induced; D000282:Administration, Intravaginal; D000284:Administration, Oral; D000328:Adult; D016001:Confidence Intervals; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D016595:Misoprostol / Q000008:administration & dosage* / Q000009:adverse effects; D015999:Multivariate Analysis; D011446:Prospective Studies; D012044:Regression Analysis
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D016595:Misoprostol; D008727:Methotrexate